European Commission Approves Revolution Medicines' RASONQUE (daraxonrasib) for Metastatic Pancreatic Cancer
The European Commission has granted approval for RASONQUE (daraxonrasib) as a once-daily oral monotherapy for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.